A novel approach to obtain stable Ru(III) complexes under physiological conditions is here presented. The general design of these new derivatives is based on the incorporation of ruthenium within amphiphilic nucle-olipids, carrying a pyridine moiety as the ligand for the transition metal. A small library of Ru-containing nucleolipids has been synthesized, co-aggregated with different phospholipids and studied in their self-aggregation behavior and antineoplastic activity. The Ru(III) complexes formulations in POPC proved to be stable for months, showing high in vitro antiproliferative activity.
Nucleolipid-based complexes of Ruthenium (III): a novel strategy in the search for effective anticancer agents / Paduano, Luigi; Mangiapia, Gaetano; D'Errico, Gerardino; Colonna, Alfredo; Irace, Carlo; L., Simeone; Montesarchio, Daniela. - (2012). (Intervento presentato al convegno XX International Roundtable on Nucleosides Nucleotides and Nucleic Acids tenutosi a Montreal, Canada nel 5-9 Agosto 2012).
Nucleolipid-based complexes of Ruthenium (III): a novel strategy in the search for effective anticancer agents
PADUANO, LUIGI;MANGIAPIA, GAETANO;D'ERRICO, GERARDINO;COLONNA, ALFREDO;IRACE, CARLO;MONTESARCHIO, DANIELA
2012
Abstract
A novel approach to obtain stable Ru(III) complexes under physiological conditions is here presented. The general design of these new derivatives is based on the incorporation of ruthenium within amphiphilic nucle-olipids, carrying a pyridine moiety as the ligand for the transition metal. A small library of Ru-containing nucleolipids has been synthesized, co-aggregated with different phospholipids and studied in their self-aggregation behavior and antineoplastic activity. The Ru(III) complexes formulations in POPC proved to be stable for months, showing high in vitro antiproliferative activity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
